With the inclusion of 10 clinical trials, comprising a sample size of 630 T1D patients, significant improvements were observed in HbA1c, FCP, and DIU, while no effects were found in FBG, CRP, TNF-α, IL-10, HDL, LDL, and the Shannon index. The gene discussed is CRP; the disease is type 1 diabetes mellitus.